6.
Capelle L, Fontaine D, Mandonnet E, Taillandier L, Golmard J, Bauchet L
. Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg. 2013; 118(6):1157-68.
DOI: 10.3171/2013.1.JNS121.
View
7.
Hervey-Jumper S, Zhang Y, Phillips J, Morshed R, Young J, McCoy L
. Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. J Clin Oncol. 2023; 41(11):2029-2042.
PMC: 10082290.
DOI: 10.1200/JCO.21.02929.
View
8.
Verdier M, Deverdun J, de Champfleur N, Duffau H, Lam P, Dos Santos T
. Evaluation of a nnU-Net type automated clinical volumetric tumor segmentation tool for diffuse low-grade glioma follow-up. J Neuroradiol. 2023; 51(1):16-23.
DOI: 10.1016/j.neurad.2023.05.008.
View
9.
Chaichana K, McGirt M, Laterra J, Olivi A, Quinones-Hinojosa A
. Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg. 2009; 112(1):10-7.
DOI: 10.3171/2008.10.JNS08608.
View
10.
Rossi M, Gay L, Ambrogi F, Conti Nibali M, Sciortino T, Puglisi G
. Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas. Neuro Oncol. 2020; 23(5):812-826.
PMC: 8099476.
DOI: 10.1093/neuonc/noaa225.
View
11.
Duffau H, Pallud J, Mandonnet E
. Evidence for the genesis of WHO grade II glioma in an asymptomatic young adult using repeated MRIs. Acta Neurochir (Wien). 2010; 153(3):473-7.
DOI: 10.1007/s00701-010-0917-x.
View
12.
Gerin C, Pallud J, Grammaticos B, Mandonnet E, Deroulers C, Varlet P
. Improving the time-machine: estimating date of birth of grade II gliomas. Cell Prolif. 2011; 45(1):76-90.
PMC: 6496223.
DOI: 10.1111/j.1365-2184.2011.00790.x.
View
13.
Mandonnet E, Pallud J, Fontaine D, Taillandier L, Bauchet L, Peruzzi P
. Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection. Neurosurg Rev. 2009; 33(1):91-6.
DOI: 10.1007/s10143-009-0229-x.
View
14.
Duffau H
. Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up. Acta Neurochir (Wien). 2015; 158(1):51-8.
DOI: 10.1007/s00701-015-2621-3.
View
15.
Pallud J, Blonski M, Mandonnet E, Audureau E, Fontaine D, Sanai N
. Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol. 2013; 15(5):595-606.
PMC: 3635513.
DOI: 10.1093/neuonc/nos331.
View
16.
Goze C, Blonski M, Le Maistre G, Bauchet L, Dezamis E, Page P
. Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas. Neuro Oncol. 2014; 16(8):1100-9.
PMC: 4096178.
DOI: 10.1093/neuonc/nou085.
View
17.
Mandonnet E
. Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma-Letter. Clin Cancer Res. 2024; 30(3):638.
DOI: 10.1158/1078-0432.CCR-23-3444.
View
18.
Blonski M, Obara T, Brzenczek C, Pouget C, Dillier C, Meyer M
. Initial PCV Chemotherapy Followed by Radiotherapy Is Associated With a Prolonged Response But Late Neurotoxicity in 20 Diffuse Low-Grade Glioma Patients. Front Oncol. 2022; 12:827897.
PMC: 8931287.
DOI: 10.3389/fonc.2022.827897.
View
19.
Di Perri D, Jmil S, Lawson T, Van Calster L, Whenham N, Renard L
. Health-related quality of life and cognitive failures in patients with lower-grade gliomas treated with radiotherapy. Cancer Radiother. 2023; 27(3):219-224.
DOI: 10.1016/j.canrad.2022.10.004.
View
20.
Desmurget M, Bonnetblanc F, Duffau H
. Contrasting acute and slow-growing lesions: a new door to brain plasticity. Brain. 2006; 130(Pt 4):898-914.
DOI: 10.1093/brain/awl300.
View